Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers
Haemonetics shares rose 12% after CSL updated its plans to transition all U.S. plasma centers to Haemonetics' NexSys devices by 2027. The deal, initially disclosed in August, was expanded from a partial to a full rollout. Haemonetics' fiscal 2026 revenue was $1.33B, with organic growth at 1.1%. The stock trades at 21x forward earnings, above its 5-year average of 19.1x.
How this was made
The 30-second read
Why it matters
The news provides a fresh, material contract update that directly drove a 12% share surge, offering a clear trading trigger.
Market read
The contract expansion is a primary catalyst for Haemonetics' stock rally and may influence the broader medical device sector.
What to watch
Potential supply chain constraints for NexSys devices could delay full rollout.
Background
Haemonetics disclosed an updated supply agreement with CSL Plasma, expanding the rollout to all U.S. centers by 2027, removing prior uncertainty.
Ticker impact
Haemonetics shares jumped 12% after CSL updated its rollout to move all U.S. plasma centers to NexSys by end‑2027.
likely upward pressure as market prices in the larger, timed CSL deal.
The deal removes uncertainty and expands a major customer, supporting a sustained price rally.
CSL (CSLLY) announced it will move all its U.S. plasma centers onto Haemonetics' NexSys devices by end‑2027.
neutral to modestly positive as the contract is already reflected in CSL's own valuation.
The announcement confirms a major procurement but does not directly alter CSL's revenue guidance.
Market effects
Strengthens the medical device and plasma collection sector by confirming a large, long‑term contract.
U.S. healthcare equipment market sees a boost from the expanded CSL partnership.
Highlights growing demand for advanced plasma collection technology worldwide.
Counterpoint
If CSL later reduces volumes or faces regulatory hurdles, the upside may be limited.
Key entities
- CompanyHaemonetics
Medical device maker supplying NexSys plasma collection systems.
- CompanyCSL Plasma
Operator of U.S. plasma collection centers, now committing to full NexSys rollout.
